Dose Conversion and Clinical Equivalence of Mycophenolate Formulations

Dose Conversion Ratios

Enteric‑coated mycophenolate sodium (EC‑MPS) 720 mg provides roughly the same exposure as 1,000 mg of mycophenolate mofetil (MMF). This conversion factor is derived from pharmacokinetic studies and is endorsed by rheumatology guidelines. 1, 2, 3, 4
Typical dosing regimens: 720–1,080 mg of EC‑MPS taken twice daily correspond to a total daily MMF dose of 2–3 g. The range reflects the 1.4:1 conversion ratio and is recommended for adult patients requiring immunosuppression. 1, 2, 5

Therapeutic equivalence: When dosed according to the established conversion ratio, MMF and EC‑MPS achieve comparable clinical efficacy in transplantation and lupus nephritis trials. Multiple rheumatology and transplant societies consider the two formulations interchangeable for efficacy purposes, provided the dose conversion is applied. 1, 2, 3, 4

Reduced GI side effects: Evidence suggests that EC‑MPS may be associated with less nausea and diarrhea than MMF, although findings are mixed and the benefit remains debated. 1, 2, 5
Switching strategy: For patients experiencing significant gastrointestinal adverse effects on MMF, transitioning to EC‑MPS at an equivalent dose (720–1,080 mg twice daily) is a reasonable clinical approach supported by dermatology literature. 6, 7

Conversion rule of thumb: Use an approximate 1.4 : 1 ratio (MMF : EC‑MPS) when converting between formulations to avoid under‑ or over‑immunosuppression. This guideline is reinforced across rheumatology and transplant recommendations. 1, 2, 3, 4